Alimta News and Research RSS Feed - Alimta News and Research

Top performing oncology drugs at risk of losing patent rights by 2022

After a period of relative stability, a glut of patent expiries is just five years away for the oncology market, according to pharmaceutical analyst Datamonitor Healthcare. [More]
Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. [More]
Market research report on injectable generic and biosimilar drugs

Market research report on injectable generic and biosimilar drugs

Reportlinker.com announces that a new market research report is available in its catalogue: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 [More]
Lilly Peers Into Future, Sees Three Drug Launches In 2014

Lilly Peers Into Future, Sees Three Drug Launches In 2014

... [More]
New forecast report on US Non-Small Cell Lung Cancer drug market

New forecast report on US Non-Small Cell Lung Cancer drug market

Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022. [More]

Personalized treatment may be effective in wild type cancers

As a woman in her mid-forties who didn't smoke, Elizabeth Lacasia never expected to be diagnosed with lung cancer. But in 2006, after she developed a persistent and serious cough, a chest X-ray and CT scan revealed several tumors in her lower left lung. [More]
Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). [More]
OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonstrating the potent anti-cancer activity of anti-DLL4 (demcizumab) in patient-derived pancreatic tumor models. [More]
Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly announces final results from ALIMTA Phase III study on NSCLC

Final results from PARAMOUNT, a Phase III study of ALIMTA (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company. [More]

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Eli Lilly and Company will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. [More]

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer [More]

Eli Lilly third quarter total revenue increases 9% to $6.148 billion

Eli Lilly and Company today announced financial results for the third quarter of 2011. [More]

African Americans more likely than Caucasians to develop and die from lung cancer

Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates, African Americans are more likely than Caucasians to develop and die from lung cancer. [More]
Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer. [More]

Lilly second quarter total revenue increases 9% to $6.253 billion

Eli Lilly and Company today announced financial results for the second quarter of 2011. [More]

Eli Lilly total revenue increases 6% to $5.839 billion for first quarter 2010

Eli Lilly and Company today announced financial results for the first quarter of 2011. [More]

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor. [More]

New discovery can provide insight into lung cancer

A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease. [More]
Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC). [More]
Lilly fourth quarter worldwide total revenue increases 4% to $6.187 billion

Lilly fourth quarter worldwide total revenue increases 4% to $6.187 billion

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2010. [More]